ClinicalTrials.gg
CompletedNCT00519142Updated Sep 17, 2009

Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus

A Phase 3 interventional study of placebo for mitiglinide and mitiglinide in Diabetes Mellitus, Type 2, sponsored by Elixir Pharmaceuticals. Completed at 61 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-09-17.

Sponsored by Elixir Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
367
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
633rd of 2,957
367 · median 90
Started
2007
with 131 others
Phase 3
580 of 3,304
34 open now
Registered
396th of 3,304
by date

Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 633rd largest by enrollment of the 2,957 interventional ones that give a count, is one of 132 that started in 2007, is one of 580 in phase 3, and was the 396th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

343 of the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

338 more — sign in →

All 343 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to demonstrate whether mitiglinide administered in combination with metformin is more effective than metformin alone in patients with Type 2 diabetes mellitus (T2DM) whose blood sugar is not well controlled taking metformin alone. This is a 24 week study which measures improvement in blood sugar after of treatment.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, parallel group study designed to evaluate the efficacy and safety of mitiglinide in combination with metformin in patients with T2DM who are less than adequately controlled on metformin alone. Patients who are receiving metformin alone for T2DM will be randomized equally into one of three treatment groups.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • type 2 diabetes diagnosed for at least 6 months
  • stable metformin usage for at least 4 months
  • 7.5% - 10.5% inclusive
  • no severe diabetic complications

Exclusion criteria

Exclusion Criteria:

  • chronic insulin use
  • use of oral diabetic agent within 12 weeks
  • acute or chronic conditions, excluding diabetes, that could compromise end point evaluation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
367 participants (actual)

Study arms

  • Placebo comparator
    1

    metformin + placebo for mitiglinide

    Drug: placebo for mitiglinide

  • Experimental
    2

    metformin + mitiglinide three times a day with meals

    Drug: mitiglinide

  • Experimental
    3

    metformin + mitiglinide two times a day with morning and evening meal, placebo for mitiglinide with midday meal

    Drug: mitiglinide

Interventions

  • Drugplacebo for mitiglinide

    three times a day with meals

  • three times a day with meals

  • two times a day with meals

06

What researchers measure

Primary outcomes

  1. change from baseline in HbA1c

    Time frame: after 24 weeks of treatment

Secondary outcomes

  1. change from baseline in 2-hour post-prandial glucose

    Time frame: after 24 weeks of treatment

  2. change from baseline in fasting plasma glucose

    Time frame: after 24 weeks of treatment

07

Study locations

61 sites
  • Elixir Study Site
    Glendale, Arizona, United States
  • Elixir Study Site
    Greenbrae, California, United States
  • Elixir Study Site
    La Jolla, California, United States
  • Elixir Study Site
    Los Angeles, California, United States
  • Elixir Study Site
    Los Gatos, California, United States
  • Elixir Study Site(s)
    Oakland Area, California, United States
  • Elixir Study Site
    Orange, California, United States
  • Elixir Study Site
    West Hills, California 91307, United States
  • Elixir Study Site
    Westlake Village, California, United States
  • Elixir Study Site
    Pueblo, Colorado, United States
  • Elixir Study Site(s)
    Washington, District of Columbia, United States
  • Elixir Study Site
    Chiefland, Florida 32626, United States
  • Elixir Study Site
    Coral Gables, Florida, United States
  • Elixir Study Site
    Kissimmee, Florida, United States
  • Elixir Study Site(s)
    Miami, Florida, United States
  • Elixir Study Site
    St. Cloud, Florida, United States
  • Elixir Study Site
    Winter Park, Florida, United States
  • Elixir Study Site
    Atlanta, Georgia 30080, United States
  • Elixir Study Site
    Austell, Georgia, United States
  • Elixir Study Site
    Perry, Georgia, United States
  • Elixir Study Site(s)
    Chicago, Illinois, United States
  • Elixir Study Site
    Wichita, Kansas, United States
  • Elixir Study Site
    Kansas City, Missouri 64132, United States
  • Elixir Study Site
    St Louis, Missouri 63110, United States
  • Elixir Study Site
    Las Vegas, Nevada, United States
  • Elixir Study Site
    Hamilton, New Jersey, United States
  • Elixir Study Site
    Hillsborough, New Jersey, United States
  • Elixir Study Site
    Sewell, New Jersey, United States
  • Elixir Study Site(s)
    New York, New York, United States
  • Elixir Study Site
    Mooresville, North Carolina, United States
  • Elixir Study Site
    Morehead City, North Carolina, United States
  • Elixir Study Site
    Akron, Ohio, United States
  • Elixir Study Site
    Cincinnati, Ohio, United States
  • Elixir Study Site
    Gallipolis, Ohio, United States
  • Elixir Study Site
    Kettering, Ohio, United States
  • Elixir Study Site
    Medford, Oregon, United States
  • Elixir Study Site
    Harleysville, Pennsylvania, United States
  • Elixir Study Site
    Levittown, Pennsylvania, United States
  • Elixir Study Site
    Uniontown, Pennsylvania, United States
  • Elixir Study Site
    Columbia, South Carolina, United States
  • Elixir Study Site
    Simpsonville, South Carolina, United States
  • Elixir Study Site
    Memphis, Tennessee, United States
  • Elixir Study Site
    Tullahoma, Tennessee, United States
  • Elixir Study Site(s)
    Dallas, Texas, United States
  • Elixir Study Site
    El Paso, Texas, United States
  • Elixir Study Site(s)
    Fort Worth, Texas, United States
  • Elixir Study Site(s)
    Houston, Texas, United States
  • Elixir Study Site
    Humble, Texas, United States
  • Elixir Study Site
    Midland, Texas, United States
  • Elixir Study Site
    N. Richland Hills, Texas, United States
  • Elixir Study Site
    New Braunfels, Texas, United States
  • Elixir Study Site
    Pearland, Texas, United States
  • Elixir Study Site
    Plano, Texas 75074, United States
  • Elixir Study Site(s)
    San Antonio, Texas, United States
  • Elixir Study Site
    Temple, Texas, United States
  • Elixir Study Site
    Norfolk, Virginia, United States
  • Elixir Study Site
    Federal Way, Washington, United States
  • Elixir Study Site
    Carolina, 00983, Puerto Rico
  • Elixir Study Site
    Fajardo, 00738, Puerto Rico
  • Elixir Study Site(s)
    Ponce, Puerto Rico
  • Elixir Study Site(s)
    San Juan, Puerto Rico
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2007
First posted
Aug 22, 2007
Start
Aug 2007
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results delay requested
Sep 16, 2009
Last update
Sep 17, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00519142
Lead sponsor
Elixir Pharmaceuticals
First posted
Aug 22, 2007
Start date
Aug 2007
Primary completion
Oct 2008
Completion
Oct 2008
Last update
Sep 17, 2009

Study contacts

Paul Martha, MD
study director · Elixir Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mitiglinide

Start the discussion